Live Breaking News & Updates on John Fraser Wright

Stay updated with breaking news from John fraser wright. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Genascence Announces First Close in Series A Financing led by Pacira BioSciences and Expands Board of Directors and Scientific Advisory Board

Proceeds will be used to advance clinical program of GNSC-001, company s lead candidate in osteoarthritis (OA) Brian Kotzin, M.D., and Jackson Streeter, M.D.,. ....

United States , National Institutes Of Health , Palo Alto , Stanford University , University Of Maryland School Medicine , Brian Kotzin , Paul Robbins , Byers Kraus , Philip Conaghan , Marcc Hochberg , Pacira Biosciences , Steven Ghivizzani , Mukundan Attur , Thomasj Schnitzer , Ron Ellis , John Fraser Wright , Thomas Chalberg , Christopherh Evans , Annahita Keravala , American Society For Gene Cell Therapy , Duke University School Of Medicine , Musculoskeletal Gene Therapy Research Laboratory , Pacira Biosciences Inc , Oncorus Inc , University Of Florida Ventures , American Society Of Gene Cell Therapy ,

Court round-up 19 January 2022

A TWENTY five year old man who assaulted another man and then brandished a knife at police officers has been handed a two-year community payback order. John Fraser Wright, of Lerwick’s Observatory, admitted assaulting the man and repeatedly striking him on the head with a. ....

Ian Cruickshank , Tommy Allan , Duncan Mackenzie , John Fraser Wright , Julia Roberts Harnett , Craig Manson , Lerwick Sheriff Court On , Fraser Wright , Ladies Drive , Lerwick Sheriff Court , Lerwick Police Station , Haldane Burgess Crescent , Gilbert Bain Hospital ,

Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritis

Share this article
PALO ALTO, Calif., May 5, 2021 /PRNewswire/
Genascence Corporation, a clinical-stage biotechnology company developing life-changing gene therapy products for prevalent musculoskeletal diseases, today announced that dosing across all three cohorts has been completed in the Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis (OA).
GNSC-001 is an adeno-associated vector (AAV) carrying a coding sequence for interleukin-1 receptor antagonist (IL-1Ra), a potent inhibitor of interleukin-1 (IL-1) signaling. IL-1 is considered one of the key mediators involved in the pathogenesis of OA, causing inflammation as well as cartilage destruction. GNSC-001 is designed to offer long-term, sustained inhibition of IL-1 following a single injection into the affected joint. ....

United States , Palo Alto , Stanford University , Paul Robbins , Philip Conaghan , Steven Ghivizzani , Mukundan Attur , John Fraser Wright , Christopher Evans , Thomas Chalberg , Christopherh Evans , Annahita Keravala , Langone Health , Scientific Co , Rocket Pharmaceuticals , University Of Florida , Grossman School Of Medicine , American Society Of Gene , University Of Minnesota , University Of Leeds , Genascence Corporation , University Of Florida College Medicine , American Society , Cell Therapy , Annual Meeting , Osteoarthritis Gene Therapy ,